Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

nt to the end of the quarter, Omeros received a payment of $12.5 million from CCIC pursuant to the terms of the settlement agreement. Omeros also received $4.9 million in net proceeds from the sale of 373,700 shares of its common stock, sold at an average price of $13.29 per share, pursuant to the company's at-the-market equity facility in October 2013.

About Omeros CorporationOmeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the Company's lead drug product, OMS302 for lens replacement surgery, is currently under review for marketing approval by both the US Food and Drug Administration and the European Medicines Agency with commercial launch planned for the second half of 2014. Omeros' five other clinical programs are focused on schizophrenia, Huntington's disease and cognitive impairment; addictive and compulsive disorders; complement-related diseases; and preventing problems associated with surgical procedures. Omeros also has a proprietary GPCR platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which are subject to the "safe harbor" created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-l
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
(Date:10/20/2014)... 2014 OncLive® is ... Center at Thomas Jefferson University has joined its ... Strategic Alliance Partnership program, the Sidney Kimmel Cancer ... raise awareness of the Center’s cutting-edge research programs, ... Clinicians and other health care professionals from the ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
(Date:10/19/2014)... October 19, 2014 The Asia-Pacific Speech ... market in Asia-Pacific with analysis and forecast of revenue. ... in 2014 to $208 million by 2019, at a ... to 2019. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... and ALACHUA, Fla., Sept. 4 ,Zimmer Holdings, Inc. ... in the orthopaedics,industry, and Tutogen Medical, Inc., a ... human (allograft) and animal,(xenograft) tissue, today announced the ... wholly owned subsidiary of Zimmer Holdings,Inc., into Europe, ...
... Ind., Sept. 4 ,Tutogen Medical, Inc. (Amex: ... products made from human (allograft) and animal,(xenograft) tissue, ... a leader,in the orthopaedics industry, today announced the ... wholly owned subsidiary of Zimmer,Holdings, Inc., into Europe, ...
... to Present at BioCentury,s Newsmakers in the Biotech,Industry, Bank of America ... ... Conferences, SEATTLE, Sept. 4 Trubion Pharmaceuticals,Inc. ... executive officer, and chairman of Trubion, will present an overview,of the ...
Cached Biology Technology:Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 2Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 3Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 4Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products 5Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 2Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 3Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 4Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products 5Trubion Pharmaceuticals to Present at Upcoming Investor Conferences 2
(Date:10/19/2014)... India over the last 30 years contributed only ... during that time, according to a new study ... ., "Energy access is fundamental to development: it ... education, communication, and health," says IIASA researcher Shonali ... energy access is widely agreed to be an ...
(Date:10/18/2014)... undiagnosed, suspected genetic conditions, a certain type of exome ... yield than traditional molecular diagnostic methods, according to a ... being released to coincide with the American Society of ... the protein­coding region of the genome (the complete set ... or organism), has been rapidly applied in research settings ...
(Date:10/17/2014)... University of Copenhagen have shown for the first time ... Cystic fibrosis patients, giving them the opportunity to get ... infections. , The study also discovered the bacterial growth ... was halted or slowed down by the immune cells. ... oxygen and helped "suffocate" the bacteria, forcing the bacteria ...
Breaking Biology News(10 mins):Improved electricity access has little impact on climate change 2Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2
... This release is available in Spanish . ... ozone levels above 50 parts per billion (ppb) along the ... costing more than $1 billion in lost crop production, according ... a 5-year study led by the National Aeronautics and Space ...
... ITHACA, N.Y. Losing weight without a grumbling stomach or ... lighter lunch, finds a new Cornell University study to be ... . Participants who ate portion-controlled lunches did not compensate ... to believe the human body does not possess the mechanisms ...
... higher-protein, lower-carbohydrate energy-restricted diet has a major positive impact ... muscle, particularly when the proteins come from dairy products. ... the Journal of Nutrition, compared three groups ... Each consumed either low, medium or high amounts ...
Cached Biology News:Monitoring ground-level ozone from space 2Foods rich in protein, dairy products help dieters preserve muscle and lose belly fat: study 2
... a tetramethylrhodamine-conjugated jetSI-ENDO (excitation at ... nm), the powerful siRNA transfection ... to determine the transfection efficiency ... and trafficking of siRNAs. More ...
... movement counts, similar to an infrared beam break ... subjects at once, in two frames of reference, ... experimental group at once, and allow social interaction ... a variety of other spatial behavior situations, including ...
... a score of movement counts, similar to an ... up to 6 subjects at once, in two ... Can outpt a sync pulse to coordinate with ... animal location and timing information to control arena ...
... features of Tracker, plus software to note when ... of the arena, and trigger a penaltyThe Spatial ... built around a video camera, frame grabber, and ... fields at once and up to 6 moving ...
Biology Products: